RADX - Wutah dodolan YoY sajrone 12 wulan kepungkur Radiopharm Theranostics Ltd

Radiopharm Theranostics (RADX) optimizes drug synthesis through external CDMO contractors, which reduces operational risks. This 12-month YoY sales chart correlates with this model, and the -19.40 metric reflects the current trend. Meanwhile, Radiopharm Theranostics (RADX) is investing in radiation safety according to ESG standards, although heavy reliance on R&D testing and the rate of capital expenditure create certain financial challenges.
Radiopharm Theranostics Limited (RADX) - rincian metrik lan laporan keuangan

This indicator measures the annual change in revenue over a rolling twelve-month period with daily data updates. By analyzing the year-over-year commercial revenue dynamics over a rolling year, an investor assesses the stability of business scaling. For Radiopharm Theranostics (RADX), this rate confirms the efficiency of the costly logistics involved in radiopharmaceuticals with short half-lives. The steady growth of the curve indicates the reliability of supply chains, while the sustainable trend confirms the fundamental viability of the business model.